A5101471546- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Protein Degradation and Inhibitors
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Inflammatory Bowel Disease
- Microscopic Colitis
- T-cell and Retrovirus Studies
- RNA modifications and cancer
- Fibroblast Growth Factor Research
- Renal and related cancers
- Crystallization and Solubility Studies
- Digestive system and related health
- Alcohol Consumption and Health Effects
- Galectins and Cancer Biology
- X-ray Diffraction in Crystallography
- Viral-associated cancers and disorders
- Blood disorders and treatments
- Peroxisome Proliferator-Activated Receptors
Saitama Medical University
2015-2024
Yamaguchi University
2024
Osaka University
2022
Kobe Pharmaceutical University
2022
Saitama International Medical Center
2013-2019
Nihon Pharmaceutical University
2018
Shinshu University
2009
University of North Carolina at Chapel Hill
2001
Keio University
1983-2001
Lexington VA Health Care System
2001
This article represents the proceedings of a symposium at 2000 ISBRA Meeting in Yokohama, Japan. The chairs were Hidekazu Tsukamoto and Yoshiyuki Takei. presentations (1) Tribute to Professor Rajendar K. Chawla, by Craig J. McClain; (2) Dysregulated TNF signaling alcoholic liver disease, McClain, S. Joshi‐Barve, D. Hill, J Schmidt, I. Deaciuc, Barve; (3) role mitochondria ethanol‐mediated sensitization liver, Anna Colell, Carmen Garcia‐Ruiz, Neil Kaplowitz, Jose C. Fernandez‐Checa; (4) A...
The European Treatment and Outcome Study (EUTOS) long-term survival (ELTS) score predicts disease-specific death in patients with chronic myeloid leukemia (CML) being treated imatinib during the phase (CP) of disease. However, it is unclear whether ELTS CML-related events or treatment responses. This study evaluated predictive value regarding prognosis response CML-CP. Clinical data were retrospectively obtained from enrolled CML Cooperative Group (CML-CSG), which included diagnosed CML-CP...
Abstract We previously conducted a randomized phase II trial of OCV-501, WT1 peptide presented by helper T cells, in elderly AML (acute myeloid leukemia) patients first remission, indicating no difference 2-year disease-free survival (DSF) between the OCV-501 and placebo groups. Here, we analyzed 5-year outcome biomarkers. Five-year DFS was 36.0% group (N = 52) 33.7% 53), with significant ( p 0.74). The peripheral mRNA levels were marginally suppressed compared group. Enhanced anti-OCV-501...
A 26-year-old man was diagnosed with B/T-type mixed-phenotype acute leukemia (MPAL-B/T) based on blasts being positive for CD19, cytoplasmic CD3, and cyCD79a, but negative myeloperoxidase. Acute lymphoblastic leukemia-based chemotherapy started, the refractory. He underwent cord blood transplantation conditioning regimen of total body irradiation plus cyclophosphamide cytarabine granulocyte-colony stimulating factor priming. Prophylaxis graft versus host disease performed short-term...
Our study aims to highlight the critical role of introduction second generation tyrosine kinase inhibitors (2nd TKIs) on prognosis patients with chronic myeloid leukemia (CML) in phase (CML-CP), as determined by European Treatment and Outcome Study (EUTOS) system. Patients who were diagnosed CML-CP before March 2009 classified into imatinib group, those after April 2nd TKI group. EUTOS high-risk exhibited significantly worse outcomes terms event-free survival (EFS), progression-free (PFS),...
Successful treatment of indolent T-cell lymphoproliferative disorder the gastrointestinal tract (ITLPDGI) by chemotherapy is rare and watchful waiting often performed for asymptomatic patients. We report a case ITLPDGI successfully treated involved field radiotherapy (IFRT). The patient presented with slow localised to stomach mild symptoms. IFRT (30 Gy/20f) was administered, after which endoscopy revealed resolution lesions blood vessel appearance, absence proliferating abnormal lymphocytes...
Mixed-phenotype acute leukemia is extremely rare as the initial presentation of chronic myeloid (CML) in blast phase (CML-BP). No treatment has been established, and differentiation from de novo BCR::ABL1-positive mixed phenotype challenging. A 53-year-old woman was diagnosed having CML-BP with mixed-phenotype (B/myeloid) onset, based on clinical course response addition to findings supporting CML. Treatment ponatinib resulted a major molecular response, deep achieved by 2 cycles sequential...
Spiro[indole-3,3'-pyrrolidine]-2'-ones were synthesized via one-pot chloroformylation-dearomatizing spirocyclization of tryptamine derivatives. Moreover, the "thio" equivalent spiro[indole-3,3'-pyrrolidine]-2'-thiones, for which synthesis and properties previously unreported, synthesized. The procedures are easily implemented, have a broad scope, transition-metal-free cheap. To demonstrate utility synthetic methodology, spiro[indole-3,3'-pyrrolidine]-2'-ones converted into heterocyclic...
Few studies have reported the outcomes of adolescents and young adults (AYAs) with chronic-phase chronic myeloid leukaemia (CML-CP) on tyrosine kinase inhibitors (TKIs).We retrospectively analysed clinical features, treatment response, long-term 42 AYA patients, in comparison to older patients. The initial therapies patients between 2001 2016 included imatinib (n = 24), dasatinib 13) nilotinib 5).In peripheral blood (PB) white cell count percentage blasts at diagnosis were significantly...